Evolution of Healing via SkinTE®
The multicomponent biologic mix rapidly seeds, stabilizes, and initiates the healing process. SkinTE immediately alters the wound bed environment by providing healthy cells and chemokines. Multicellular segments engrafting post-application serve as a cellular source to the wound bed.
SkinTE® Innovation – Full Skin Barrier Reconstitution with an Autologous Heterogeneous Skin Construct (AHSC)
Harvest
Skin harvest has all the layers of healthy skin that is needed to regenerate and heal.
SkinTE
Manufactured to create “organoid-like,” multi-cellular structures of the cells and matrix needed to heal.
Application
Cells are activated in the manufacturing process. The mixture is planted into the wound.
Healing
SkinTE regenerates and activates the tissue surrounding the wound to heal the wound completely.
Multicomponent Biologic Mix Rapidly Seeds, Stabilizes and Initiates Healing Process
SkinTE immediately alters environment by providing healthy cells and chemokines
Multicellular segments engrafting post application serve as cellular source to wound bed
Epithelialization is initiated from multicellular segments within and around the wound closing the wound from inside out and outside in
The cost of diabetes care
$53,779
is the average cost of
inpatient care for a major
amputation per patient¹
60%
of people with diabetes develop neuropathy that can lead to a DFU⁴
49%
of people with a DFU experience recurrence in the first year²
85%
of diabetes-related amputations are preceded by a DFU, and can be avoided³
Diabetes directly cost $237 billion in the U.S. with one-third of these direct costs due to foot disease.
1. Hicks CW, Selvarajah S, Mathioudakis N, et al. Trends and determinants of costs associated with the inpatient care of diabetic foot ulcers. Journal of Vascular Surgery https://doi.org/10.1016/j.jvs....
2. Oliver T and Mutluoglu M, Diabetic Foot Ulcer. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/b...
3. David G. Armstrong, D.P.M., M.D., Ph.D., Andrew J.M. Boulton, M.D., and Sicco A. Bus, Ph.D. Diabetic Foot Ulcers and Their Recurrence. N Engl J Med 2017;376:2367-75.
4. APMA, Diabetic Wound Care. https://www.apma.org/diabeticw....
SkinTE Publications
Pipeline
Latest News
Science and Medicine Driven Management
-
John Stetson
CEO
• CFO & Director of PolarityTE 2016-18
• CFO & Director of Marathon (MARA) 2012-15
• University of Pennsylvania
-
Nikolai Sopko, MD, PhD
COO & CSO
• CSO of PolarityTE 2018-2023
• Johns Hopkins Urologic Surgery
• MD from Case Western
• PhD Stem Cell Biology – Case Western
-
Ned Swanson, MD
President & CMO
• Co-Founder & CMO PolarityTE 2016-2021
• Johns Hopkins Plastic Surgery Resident
• MD from Harvard Medical School
• Bioengineering University of Pennsylvania
-
Parker Scott
CFO
• Former research analyst at a leading investment bank and portfolio analyst at a multi-billion dollar special situations hedge fund.
• Experience leading public startups in the biotech, digital asset mining, and nuclear energy sectors
-
Marytheresa Ifediba, PhD
VP of R&D
• PhD from Harvard University in Bioengineering
• Expertise in therapeutic nanoparticle development for treatment of neurological damage & cancer
-
Nicholas Baetz, PhD
VP of Manufacturing
• Research Associate, Epithelial and Stem Cell biology, Vanderbilt and Johns Hopkins
• PhD, Cell Biology, University of Arizona
-
Ashlee Fishleigh
VP of Clinical Ops
• 20 years clinical trials management
• Designed, implemented, and managed Phase I through Phase IV trials
• Oversaw all seven of Polarity’s wound care trials
Contact Us
PolarityTE Headquarters
1960 South 4250 West
Salt Lake City, UT 84104
Investor Relations
Parker Scott
IR@polaritybio.com
Call Us
Corporate Main: 800-560-3983
Expanded Access Program
At PolarityBio, we are committed to developing innovative treatments for patients with complex wounds. Our investigational therapies undergo rigorous clinical testing to ensure their safety and efficacy. While participation in clinical trials is the preferred method for accessing investigational medicines, we understand that some patients may not be eligible for a trial. In certain circumstances, we may provide access to our investigational therapies through our Expanded Access Program (EAP), also known as Compassionate Use.
Physicians who believe their patient may benefit from access to an investigational therapy should contact us at EAP@polaritybio.com. Each request is carefully evaluated on a case-by-case basis in accordance with regulatory requirements and company policies. Submissions can expect a response within 2 weeks of receipt.
We encourage patients and healthcare providers to explore participation in our ongoing clinical trials where possible. Information on our active clinical trials can be found at ClinicalTrials.gov.
While we strive to assist patients in need, Expanded Access is not guaranteed and remains at the discretion of PolarityBio. Decisions are based on scientific and medical considerations and supply constraints of the investigational product.